Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Felbamate
Drug ID BADD_D00871
Description Felbamate is an anticonvulsant drug used in the treatment of epilepsy. In particular, in the adult patient population, it can be employed to treat partial seizures (with and without generalization). Alternatively, it is used to treat partial and generalized seizures associated with Lennox-Gastaut syndrome in children. It has a weak inhibitory effect on GABA receptor binding sites.
Indications and Usage For use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use.
Marketing Status approved
ATC Code N03AX10
DrugBank ID DB00949
KEGG ID D00536
MeSH ID D000078328
PubChem ID 3331
TTD Drug ID D05KON
NDC Product Code 51672-4186; 0037-0442; 65162-686; 65162-735; 42385-721; 72578-057; 51672-4172; 62559-730; 62559-731; 63629-1937; 63629-1944; 73223-003; 65162-734; 17381-554; 47621-054; 47781-630; 66689-825; 0037-0430; 70771-1077; 47781-627; 70771-1078; 70954-051; 51525-0431; 0037-0431; 72578-056; 46016-2542; 69988-0032; 51525-0442; 51672-4185; 53746-734; 53746-735; 22365-007; 16714-775; 51525-0430
UNII X72RBB02N8
Synonyms Felbamate | 2-Phenyl-1,3-propanediol dicarbamate | 2 Phenyl 1,3 propanediol dicarbamate | Taloxa | Felbatol | Felbamyl | ADD-03055 | ADD 03055 | ADD03055 | (3-Carbamoyloxy-2-phenyl-propyl) carbamate | W-554 | W 554 | W554
Chemical Information
Molecular Formula C11H14N2O4
CAS Registry Number 25451-15-4
SMILES C1=CC=C(C=C1)C(COC(=O)N)COC(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Henoch-Schonlein purpura01.01.04.001; 10.02.02.004; 23.06.01.002; 24.07.06.003---
Hepatic failure09.01.03.002--
Hepatitis09.01.07.004---
Hepatorenal syndrome09.01.03.007; 20.01.03.012---
Hiccups07.01.06.009; 22.12.01.001--
Hyperammonaemia09.01.02.002; 14.10.01.001---
Hyperglycaemia05.06.02.002; 14.06.02.002--
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypernatraemia14.05.04.001--
Hyperpyrexia08.05.02.002---
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypocalcaemia14.04.01.004--
Hypochromic anaemia01.03.02.004---
Hypoglycaemia05.06.03.001; 14.06.03.001--
Hypokalaemia14.05.03.002--
Hypomagnesaemia14.04.02.001--
Hyponatraemia14.05.04.002--
Hypophosphataemia14.04.03.001--
Hypotension24.06.03.002--
Hypothermia08.05.01.003; 12.05.03.001--
Ileus07.13.01.001--
Increased appetite08.01.09.027; 14.03.01.003---
Infection11.01.08.002---
Influenza like illness08.01.03.010--
Insomnia17.15.03.002; 19.02.01.002--
Intestinal obstruction07.13.01.002---
Jaundice01.06.04.004; 09.01.01.004; 23.03.03.030---
Leukaemia01.10.03.001; 16.01.03.001--
Leukocytosis01.02.01.002--
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 8 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene